Product Description: Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers. [1][2][3].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Herbst RS, et al. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res. 2010 Dec 1;16(23):5883-91. /[2]Kaplan-Lefko PJ, et al. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol Ther. 2010 Apr 15;9(8):618-31.
CAS Number: 896731-82-1
Molecular Weight: 145.65 (kDa)
Compound Purity: 98.90
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: TNF Receptor
English
Deutsch
